Provided by Tiger Trade Technology Pte. Ltd.

LUCID DIAGNOSTICS INC.

1.22
+0.07006.09%
Post-market: 1.220.00000.00%19:59 EST
Volume:1.05M
Turnover:1.27M
Market Cap:167.42M
PE:-1.55
High:1.24
Open:1.17
Low:1.16
Close:1.15
52wk High:1.80
52wk Low:0.9400
Shares:137.23M
Float Shares:96.17M
Volume Ratio:1.06
T/O Rate:1.09%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7866
EPS(LYR):-1.0497
ROE:-331.24%
ROA:-79.17%
PB:-5.89
PE(LYR):-1.16

Loading ...

Company Profile

Company Name:
LUCID DIAGNOSTICS INC.
Exchange:
NASDAQ
Establishment Date:
2018
Employees:
72
Office Location:
360 Madison Avenue,25th Floor,New York,New York,United States
Zip Code:
10017
Fax:
- -
Introduction:
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.

Directors

Name
Position
Lishan Aklog
Chairman and Chief Executive Officer
Stanley N. Lapidus
Vice Chairman and Director
Debra J. White
Director
Dennis A. Matheis
Director
Jacque J. Sokolov
Director
James L. Cox
Director
John R. Palumbo
Director
Ronald M. Sparks
Director

Shareholders

Name
Position
Lishan Aklog
Chairman and Chief Executive Officer
Shaun M. O'Neil
President and Chief Operating Officer
Dennis M. McGrath
Chief Financial Officer
Michael A. Gordon
General Counsel and Secretary